KTTA’s PAS-004 advances Phase 1 for NF1 and MAPK-driven cancers
PAS-004 is advancing through Phase 1 trials for NF1 and MAPK-driven cancers, aiming to address major unmet needs with improved dosing and tolerability. Early data point to promising efficacy and safety, especially for NF1-CN.